Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Oct 6;17(10):e0267423.
doi: 10.1371/journal.pone.0267423. eCollection 2022.

The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis

Hosein Nakhaee  1 , Moein Zangiabadian  2 , Reza Bayati  1 , Mohammad Rahmanian  1 , Amir Ghaffari Jolfayi  1 , Sakineh Rakhshanderou  3
Affiliations
Meta-Analysis

The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis

Hosein Nakhaee et al. PLoS One. .

Abstract

Introduction: Clinical Depression and the subsequent low immunity is a comorbidity that can act as a risk factor for the severity of COVID-19 cases. Antidepressants such as Selective serotonin reuptake inhibitor and Serotonin-norepinephrine reuptake inhibitors are associated with immune-modulatory effects, which dismiss inflammatory responses and reduce lung tissue damage. The current systematic review and meta-analysis aims to evaluate the effect of antidepressant drugs on the prognosis and severity of COVID-19 in hospitalized patients.

Methods: A systematic search was carried out in PubMed/Medline, EMBASE, and Scopus up to June 14, 2022. The following keywords were used: "COVID-19", "SARS-CoV-2", "2019-nCoV", "SSRI", "SNRI", "TCA", "MAOI", and "Antidepressant". A fixed or random-effect model assessed the pooled risk ratio (RR) with 95% CI. We considered P < 0.05 as statistically significant for publication bias. Data were analyzed by Comprehensive Meta-Analysis software, Version 2.0 (Biostat, Englewood, NJ).

Results: Fourteen studies were included in our systematic review. Five of them were experimental with 2350, and nine of them were observational with 290,950 participants. Eight out of fourteen articles revealed the effect of antidepressants on reducing the severity of COVID-19. Selective serotonin reuptake inhibitors drugs, including Fluvoxamine, Escitalopram, Fluoxetine, and Paroxetine, and among the Serotonin-norepinephrine inhibitors medications Venlafaxine, are reasonably associated with reduced risk of intubation or death. Five studies showed no significant effect, and only one high risk of bias article showed the negative effect of antidepressants on the prognosis of Covid-19. The meta-analysis of clinical trials showed that fluvoxamine could significantly decrease the severity outcomes of COVID-19 (RR: 0.763; 95% CI: 0.602-0.966, I2: 0.0).

Findings: Most evidence supports that the use of antidepressant medications, mainly Fluvoxamine, may decrease the severity and improve the outcome in hospitalized patients with SARS-CoV-2. Some studies showed contradictory findings regarding the effects of antidepressants on the severity of COVID-19. Further clinical trials should be conducted to clarify the effects of antidepressants on the severity of COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of study selection for inclusion in the systematic review and meta-analysis.
Fig 2
Fig 2. Pooled RR for clinical trials.
Fig 3
Fig 3. The funnel plot of analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Organization, W.H. WHO Coronavirus (COVID-19) Dashboard. 2022; Available from: https://covid19.who.int/.
    1. Huang C., et al.., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395(10223): p. 497–506. - PMC - PubMed
    1. Hao F., et al.., Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun, 2020. 87: p. 100–106. doi: 10.1016/j.bbi.2020.04.069 - DOI - PMC - PubMed
    1. Das A., et al.., Susceptibility of clinically depressed patients to COVID-19: Is there a link? Indian J Psychiatry, 2021. 63(1): p. 112–113. doi: 10.4103/psychiatry.IndianJPsychiatry_850_20 - DOI - PMC - PubMed
    1. Andersson N.W., et al.., Depression and the risk of severe infections: prospective analyses on a nationwide representative sample. Int J Epidemiol, 2016. 45(1): p. 131–9. - PubMed